A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women

NCT01143194 | Completed Phase 1

• 1 other identifier: 2009-11-06-OREG
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to investigate the effects of the dietary supplement oréVida™ (active ingredient on the basis of a culinary herb)administered twice daily in an acute study on an improvement in vigilance, attention, concentration, memory and mood in 45 healthy men and pre-menopausal women, aged 35-50 years, inclusive. oréVida™ is considered a dietary supplement, and therefore it is not an approved drug by the Food and Drug Administration (FDA). It is regulated like a food. The U.S. Food and Drug Administration does not strictly regulate herbs and dietary supplements. We do not claim that this supplement is meant to treat any ailment.

Conditions

Attention; Memory; Alertness

Keywords

Attention; Vigilance; Concentration; Memory; Healthy Volunteer

Outcome Measures

Primary Outcomes (1)

• Vigilance, Attention, and Concentration Tasks

  Cognitive Drug Research (CDR) Test Battery Attention: * Simple Reaction Time (Speed (msec)) * Digit Vigilance (Speed (msec)/ Targets detected (%)) * Choice Reaction Time(Speed (msec))

  4 times one day (at each test day, tasks 13 times repeated)

Secondary Outcomes (3)

• Working Memory & Executive Function Tasks

  4 times one day (at each test day, tasks 7 times repeated)

• Episodic Secondary Memory Tasks

  4 times one day (at each test day, tasks 7 times repeated)

• Additional Measurements / Questionnaires

  4 times one day (at each test day, VAS 13 times repeated / POMS 3 times repeated)

Study Arms (4)

oréVida™ 60mg/day

EXPERIMENTAL

Dietary Supplement: oréVida™

oréVida™ 120mg/day (1)

EXPERIMENTAL

Dietary Supplement: oréVida™

oréVida™ 120mg/day (2)

EXPERIMENTAL

Dietary Supplement: oréVida™

Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Interventions

oréVida™ DIETARY_SUPPLEMENT

1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)

oréVida™ 60mg/day

Placebo DIETARY_SUPPLEMENT

1 capsule of placebo twice a day

Placebo

Eligibility Criteria

• Age: 35 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subject is a male or pre-menopausal female, 35-50 years, inclusive. Post-menopausal is defined as a history of spontaneous amenorrhea for a period of 12 consecutive months or six weeks post-surgical bilateral oophorectomy, with or without hysterectomy.
• Subject is willing to maintain his or her habitual diet and usual physical activity patterns throughout the study.
• Subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Investigator on the basis of medical history and routine laboratory test results.
• Subject has a body mass index (BMI) of ≥20.00 and \<30.00 kg/m2
• Subject is willing to refrain from consuming alcohol 24 h prior to test days.
• Subject is willing to refrain from consuming caffeine and caffeine-containing products 12 h prior to test days.
• Subject is willing to refrain from vigorous physical activity 12 h prior to test days.
• Subject is a non-smoker.
• Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

You may not qualify if:

• Subject has a positive drug screening of amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, methamphetamines, methadone, 3,4-methylenedioxymethamphetamine, opiates or tricyclic antidepressants at screening.
• Subject has abnormal laboratory test results of clinical significance, including, but not limited to: creatinine ≥1.5 mg/dL, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5X the upper limit of normal at screening.
• Subject has donated more than 300 mL of blood during the three months prior to screening.
• Subject has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg) as defined by the average blood pressure measured at screening. One re-test will be allowed on a separate day prior to visit 2, day 0 for subjects whose blood pressure exceeds either of these cut points at visit 1.
• Subject has a history or presence of clinically important cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorders that, in the judgment of the Investigator, would interfere with the subject's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the subject at undue risk.
• Subject has a history, in the judgment of the Investigator, of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.
• Use of any sleep aid medication within four days prior to each test day.
• Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.
• Subject is pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential who are unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded in the source documentation.
• Excessive habitual caffeine consumption (\>300 mg caffeine/d or ≥3 cups of caffeinated coffee/d), following screening and throughout the study period.
• Use of any psychotropic medication within four weeks of screening and throughout the study.
• Use of antibiotics or signs of active systemic infection. Treatment visits will be rescheduled to allow the subject to wash off of the antibiotic for at least five days prior to any test visit.
• Subject has had exposure to any non-registered drug product within 30 days prior to the screening visit.
• Use of dietary supplements containing any of the following: ginkgo biloba, St. John's wort, ginseng, gotu kola (Indian pennywort); daily doses of vitamin E (≥30 mg/d) or folic acid (≥400 ug/d); thiamine, riboflavin, and/or pyridoxine (≥2 mg/d); and eicosapentaenoic acid (EPA), docosahexaenoic acid or a combination of EPA + DHA (≥500 mg/d) within 2 weeks of screening visit.
• Recent history of (within 12 months of screening visit 1) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).

Sponsors & Collaborators

• DSM Nutritional Products, Inc.: lead

Study Sites (1)

Provident Clinical Research

Addison, Illinois, 60101, United States

Location

Study Officials

• Kathleen Kelley, MD

  Provident Clinical Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: June 11, 2010
• First Posted: June 14, 2010
• Study Start: March 1, 2010
• Primary Completion: November 1, 2010
• Study Completion: November 1, 2010
• Last Updated: June 9, 2011

Record last verified: 2011-06

Locations

US (1)